Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: the IMMEDIATE trial

被引：6

作者：

Ellis, K. L. ^{[1
]}

Zhou, Y. ^{[2
]}

Beshansky, J. R. ^{[3
]}

Ainehsazan, E. ^{[1
]}

Yang, Y. ^{[1
]}

Selker, H. P. ^{[3
]}

Huggins, G. S. ^{[4
]}

Cupples, L. A. ^{[2
]}

Peter, I. ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA

[2] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA

[3] Tufts Univ, Sch Med, Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA

[4] Tufts Med Ctr, Ctr Translat Genom, Mol Cardiol Res Inst, Boston, MA USA

来源：

PHARMACOGENOMICS JOURNAL | 2015年 / 15卷 / 01期

基金：

美国国家卫生研究院;

关键词：

GENOME-WIDE ASSOCIATION; ACUTE CORONARY SYNDROMES; RANDOMIZED CONTROLLED-TRIAL; TYPE-2 DIABETES RISK; INTRAVENOUS GLUCOSE; SUSCEPTIBILITY LOCI; VARIANTS; METAANALYSIS; SEQUENCE; RELEASE;

D O I：

10.1038/tpj.2014.41

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

The mechanistic effects of intravenous glucose, insulin and potassium (GIK) in cardiac ischemia are not well understood. We conducted a genetic sub-study of the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care (IMMEDIATE) Trial to explore effects of common and rare glucose and insulin-related genetic loci on initial to 6-h and 6- to 12-h change in plasma glucose and potassium. We identified 27 NOTCH2/ADAM30 and 8 C2CD4B variants conferring a 40-57% increase in glucose during the first 6 h of infusion (P < 5.96 x 10(-6)). Significant associations were also found for ABCB11 and SLC30A8 single-nucleotide polymorphisms (SNPs) and glucose responses, and an SEC61A2 SNP with a potassium response to GIK. These studies identify genetic factors that may impact the metabolic response to GIK, which could influence treatment benefits in the setting of acute coronary syndromes (ACS).

引用

页码：55 / 62

页数：8

共 50 条

[1] Genetic variation at glucose and insulin trait loci and response to glucose–insulin–potassium (GIK) therapy: the IMMEDIATE trial
K L Ellis
Y Zhou
J R Beshansky
E Ainehsazan
Y Yang
H P Selker
G S Huggins
L A Cupples
I Peter
The Pharmacogenomics Journal, 2015, 15 : 55 - 62
[2] Genetic modifiers of response to glucose-insulin-potassium (GIK) infusion in acute coronary syndromes and associations with clinical outcomes in the IMMEDIATE trial
Ellis, K. L.
Zhou, Y.
Beshansky, J. R.
Ainehsazan, E.
Selker, H. P.
Cupples, L. A.
Huggins, G. S.
Peter, I.
PHARMACOGENOMICS JOURNAL, 2015, 15 (06): : 488 - 495
[3] USE OF GLUCOSE-INSULIN-POTASSIUM (GIK) IN HUMAN SEPTIC SHOCK
BRONSVELD, W
VANDENBOS, GC
THIJS, LG
CRITICAL CARE MEDICINE, 1985, 13 (07) : 566 - 570
[4] GLUCOSE-INSULIN-POTASSIUM (GIK) REGIMEN IN TREATMENT OF MYOCARDIAL ISCHEMIA
BRACHFELD, N
CIRCULATION, 1973, 48 (03) : 459 - 462
[5] REDUCTION OF MYOCARDIAL OXYGEN DEMAND BY GLUCOSE-INSULIN-POTASSIUM (GIK)
HANEDA, T
GANZ, W
LEE, T
KATZ, J
CIRCULATION, 1974, 50 (04) : 102 - 102
[6] EXPERIMENTAL CORONARY-OCCLUSION AND GLUCOSE-INSULIN-POTASSIUM (GIK)
HOFMANN, M
HOFMANN, M
SCHAPER, W
ZEITSCHRIFT FUR KARDIOLOGIE, 1980, 69 (03): : 240 - 240
[7] Insulin concentrations from stored glucose-insulin-potassium ('GIK') solutions: an improved system
McAnulty, GR
Robertshaw, HJ
Berge, D
Barnardo, P
BRITISH JOURNAL OF ANAESTHESIA, 1999, 82 : 129 - 129
[8] ACUTE MYOCARDIAL INFARCTION TREATED BY GLUCOSE-INSULIN-POTASSIUM (GIK) INFUSION
SIEVERS, J
LINDH, J
JOHANSSON, BW
KARNELL, J
CARDIOLOGIA, 1966, 49 (04): : 239 - +
[9] EFFECTS OF GLUCOSE-INSULIN-POTASSIUM (GIK) ON MYOCARDIAL FUEL CONSUMPTION (MFC)
STANLEY, AW
MORASKI, RE
RUSSELL, RO
RACKLEY, CE
KREISBER.RA
CIRCULATION, 1973, 48 (04) : 221 - 221
[10] Revival of glucose-insulin-potassium infusion (GIK) for acute myocardial infarction
不详
DIABETES OBESITY & METABOLISM, 1999, 1 (01): : 62 - 62

← 1 2 3 4 5 →